Why Pan-Cancer Immunotherapy Is a Biotech Goldmine
How tissue-agnostic therapies are expanding markets, accelerating approvals, and lowering risk across oncology portfolios
TL;DR: The smartest bets aren’t single-use. Pan-cancer drugs turn immune insight into portfolio power.
One drug can treat many cancers by targeting shared biomarkers like MSI-H or TMB, regardless of tumor location.
Pan-cancer biomarkers are found in over 20% of tumors, greatly expanding the market opportunity for a single therapy.
The FDA is enabling faster, tissue-agnostic approvals through biomarker-guided basket trials.
Immunotherapies often deliver long-lasting responses and immune memory, driving durable value.
A single pan-cancer asset can unlock multiple indications, lowering development risk and increasing return potential.
Capital is flowing into biomarker-first oncology strategies as the next generation of blockbusters emerges.
Pan-cancer (or tissue-agnostic) immunotherapies treat tumors based on shared molecular features, not the organ of origin. In practice, this means a single drug can potentially work against any cancer that carries the right biomarker. The U.S. FDA has already approved several immune-targeted drugs using this principle. For example, anti-PD-1 checkpoint inhibitors block the “brakes” on a patient’s T-cells (immune cells), allowing them to attack cancer across the body. Often these therapies require a companion test, such as microsatellite instability-high (MSI-H) or high tumor mutational burden (TMB), to identify patients likely to respond. In short, pan-cancer immunotherapies harness the immune system to attack any tumor with the right profile.
How Pan-Cancer Immunotherapies Work
Checkpoint inhibitors (like pembrolizumab or dostarlimab) are antibodies that target immune checkpoints on T-cells or tumor cells. For instance, PD‑1 is a receptor on T-cells; blocking PD‑1 or its partner PD‑L1 lifts the natural “brakes” on the immune response. When that happens, T-cells can recognize and kill cancer cells throughout the body. Tumors with many mutations, for example MSI-H (mismatch-repair-deficient) cancers or tumors with high TMB, tend to present many new antigens on their surface. These “hot” tumors become especially susceptible once the immune system is unleashed. In fact, FDA labels for pembrolizumab now cover any solid tumor that is MSI-H/dMMR or even any solid tumor with TMB ≥10 mutations/Mb. (Dostarlimab similarly covers MSI-H/dMMR cancers.)
Biomarker-driven selection is key: instead of “lung cancer” or “breast cancer,” the indication is the biomarker (e.g. MSI-H). In 2017 the FDA approved pembrolizumab for any MSI-H/dMMR solid tumor, the first tissue-agnostic approval. Since then, more tumor-agnostic immunotherapy approvals have followed (see Figure). Under the hood, what this means is companies can run basket trials enrolling many tumor types that share a marker. For example, trials like NCI-MATCH and ASCO-TAPUR are enrolling patients by genetic profile, not by cancer site. This design taps broader patient pools and can speed up enrollment, especially in rare cancers.
The Pan-Cancer Advantage
Pan-cancer immunotherapies offer several compelling advantages for drug developers and investors:
Larger patient population. By agnostic design, the same drug can treat multiple cancers. One analysis of ~300,000 real-world tumors found 21.5% had at least one tissue-agnostic biomarker. That translates into millions of additional eligible patients. Some of those (about 5%) had no cancer-specific therapy available, meaning a pan-cancer drug could be their first targeted option. In practice, this broad reach can dramatically grow a therapy’s addressable market.
Regulatory efficiency. The FDA now actively supports tumor-agnostic development. In 2022 it even issued draft guidance on tissue-agnostic oncology drugs. Companies can submit one application for a biomarker-based indication that spans dozens of tumor types. Instead of five separate trials (one per cancer), a single multi-arm “basket” trial can suffice. This streamlines development and can shorten time-to-market.
Innovative trial design. As noted above, basket trials let each patient enroll based on a molecular marker. This is ideal for rare mutations or cancers. The concept is simple: one therapy, many tumor types. It allows resource sharing and Bayesian designs to borrow strength across cohorts, often requiring smaller sample sizes for rare groups. For example, the NCI-MATCH and ASCO-TAPUR studies are pioneering these tissue-agnostic trials. Such designs can also focus on novel endpoints (like overall biomarker response) and real-world evidence to support approval.
Durable immune memory. Unlike chemotherapy, immunotherapy can induce long-lived remissions. Many responding patients experience complete or partial remissions that last years. In clinical trials of pan-cancer checkpoint drugs, responses tend to be durable: e.g., in KEYNOTE studies over 78% of responders to pembrolizumab were still responding at 6 months. Immune “memory” means the body’s T-cells may keep surveillance even after treatment ends. For patients, this means a shot at long-term control; for investors, it means outcomes (and thus drug value) that extend well beyond the treatment window.
Scalable commercial potential. A pan-cancer asset is inherently “de-risked” compared to a one-cancer drug. Even if a trial arm in one indication fails, others may succeed. From a business standpoint, a single successful Phase 3 can spawn multiple indications and label expansions. In effect, companies get “multiple shots on goal” from one development program. This scale-up logic tends to make these assets more valuable. Indeed, industry reports note growing investment in tumor-agnostic programs as pharmaceutical R&D shifts to agnostic therapies that “widen [a drug’s] potential application” across cancers.
FDA-Approved Pan-Cancer Therapies
Today, the FDA has approved nine tissue-agnostic cancer therapies across different categories. Several of these are immunotherapies. The graphic above summarizes the current landscape. Key examples include:
Pembrolizumab (Keytruda). In May 2017 it became the first-ever tumor-agnostic drug, approved for any unresectable or metastatic solid tumor that is MSI-H/dMMR. In 2020 this indication was expanded to include any solid tumor with TMB ≥10 mut/Mb. By March 2023, Keytruda received full (not just accelerated) approval in the MSI-H/dMMR setting based on pooled data from 504 patients in 30+ cancers. Across those studies, the objective response rate was around 34-40% overall , including complete remissions in some patients, and most responders had durable benefit.
Dostarlimab (Jemperli). An anti-PD-1 antibody like Keytruda, dostarlimab earned an accelerated approval in August 2021 for any recurrent or advanced solid tumor with dMMR. It essentially mirrors Keytruda’s MSI-H/dMMR label, giving patients another PD-1 option. Clinical trials continue to pool diverse dMMR cancers, confirming that many tumor types can respond to PD-1 blockade if that biomarker is present.
Basket trial approvals. Beyond MSI/TMB, the pan-cancer concept extends to other biomarkers. For example, the NTRK inhibitors larotrectinib and entrectinib are approved for any solid tumor with an NTRK gene fusion , and selpercatinib is approved for RET-fusion tumors. Even a HER2-targeted antibody-drug conjugate, trastuzumab deruxtecan (Enhertu), recently received a tumor-agnostic nod for any HER2 IHC3+ solid tumor. These examples (mostly targeted rather than immuno) underscore how tissue-agnostic drug development is now mainstream. Immune checkpoint drugs lead the pack, but their success has paved the way for this model across oncology.
Ongoing trials. Many new immunotherapy assets are being tested in basket or umbrella trials. For instance, the KEYNOTE-158 trial enrolled patients with various tumor types and biomarkers (MSI-H, TMB-H, etc.) to test pembrolizumab in a multi-cancer setting. Other studies pair PD-1 inhibitors with targeted agents across cancers. This trend is accelerating thanks to FDA encouragement and real-world sequencing initiatives.
Why Investors Should Take Note
For biotech investors, pan-cancer immunotherapies represent a derisked, high-leverage opportunity in oncology. Instead of a one-off indication, each drug can unlock multiple markets. A drug that works in lung, colon, endometrial and many other cancers carries much bigger peak sales potential than a tumor-specific therapy. Because of this, analysts and venture funds are increasingly eying tissue-agnostic pipelines. Citeline reports that 2024 saw “increased investment in tumor-agnostic therapies” as companies chase broader genetic targets.
Moreover, the regulatory environment is favorable: the FDA’s tissue-agnostic guidance and history of approvals mean drug developers can plan smarter, more efficient trials. One positive trial readout can justify multiple label expansions, so the “value per study” is higher. In practice this leads to higher valuations. Biotech pipelines with pan-cancer strategies tend to attract premium financing, since investors can imagine multiple exits (through partnerships or approvals) from a single asset.
Importantly, pan-cancer immunotherapy also addresses high unmet needs. Many patients (especially with rare or heavily pre-treated cancers) have no effective options. Tissue-agnostic immunotherapies “offer a promising alternative where few exist”. This widens the potential patient base and underscores the blockbuster promise. As one expert put it, oncology is in the midst of “a seismic shift”, moving from organ-based drugs to molecularly-driven, tissue-agnostic treatments. In this new paradigm, drugs are valued more for the genetic alterations they target than the cancer label they carry.
In summary, pan-cancer immunotherapies combine the scientific power of precision oncology with broad-market economics. For investors, that translates into a more scalable, de-risked portfolio. With multiple FDA tumor-agnostic approvals already on the books and more in the pipeline, this approach is reshaping how oncology assets are developed and valued. The future of cancer therapy, and the next wave of biotech winners, will likely be built on these biomarker-driven, tissue-agnostic platforms.
Sources: Peer-reviewed studies, FDA announcements and recent analyses of tumor-agnostic drug development.